Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: A retrospective study

Clinical Endocrinology

Volumn 51, Issue 2, 1999, Pages 159-164

  Razzore, P ^b   Colao, A ^b   Baldelli, R ^b   Gaia, D ^b   Marzullo, P ^b   Ferretti, E ^b   Ferone, D ^b   Jaffrain Rea, M L ^b   Tamburrano, G ^b   Lombardi, G ^b   Camanni, F ^b   Ciccarelli, Enrica ^a  

^a City of Health and Science Torino   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; LANREOTIDE SR; OCTREOTIDE; UNCLASSIFIED DRUG;

ACROMEGALY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG SAFETY; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; THYROID FUNCTION; TREATMENT PLANNING;

EID: 0032795782     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00812.x     Document Type: Article

References (43)

1. Alexander, L., Appleton, D., Hall, R., Ross, W.M. & Wilkinson, R. (1980) Epidemiology of Acromegaly in the Newcastle region. Clinical Endocrinology, 12, 71-79.
2. Al-Maskari, M., Gebbie, J. & Kendall-Taylor, P. (1996) The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical Endocrinology, 45, 415-421.
3. Arosio, M., Macchelli, S., Rossi, C.M., Casati, G., Biella, O. & Faglia, G. (1995) Effects of treatment with octreotide in acromegalic patients: a rnulticenter Italian study. European Journal of Endocrinology, 133, 430-439.
4. Baldelli, R., Ferretti, E., Jaffrain-Rea, M.L., Iacobellis, G., Minniti, G., Caracciolo, B., Moroni, C., Cassone, R., Gulino, A. & Tamburrano, G. (1999) Cardiac effects of slow release lanreotide, a slow release sumatostatin analog, in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 84, 527-532.
5. Barkan, A.L., Halasz, I., Dornfeld, K.J., Jaffe, C.A., Friherg, R.D., Chandler, W.F. & Sandler, H.M. (1997) Pituitary irradiation is ineffective in normalising plasma insulin-like growth factor 1 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 82, 3187-3191.
6. Bates, A., van't Hoff, W., Jones, J.M. & Clayton, R.N. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
7. Bates, A., van't Hoff, W., Jones, J. & Clayton, R. (1995) Does treatment of acromegaly affect life expectancy? Metabolism, 44, 1-5.
8. Bengtsson, B., Eden, S., Ernest, I., Oden, A. & Sjogren, B. (1988) Epidemiology and long term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica, 223, 327-335.
9. Caron, P., Cogne, M., Gusthiot-Joudet, B., Wakim, S., Catus, F. & Bayard, F. (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). European Journal of Endocrinology, 132, 320-325.
10. Caron, P., Morange-Ramos, I., Cogne, M. &Jaquet, P. (1997) Three year follow-up of acromegalic patients treated with intramuscolar slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
11. Clayton, R.N. (1997) New developments in the management of acromegaly. Should we achieve absolute biochemical cure? Journal of Endocrinology, 155, S23-29
12. Cheung, N.W. & Boyages, S.C. (1997) Increased incidence of neoplasia in females with acromegaly. Clinical Endocrinology, 47, 323-327.
13. Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Merola, B., Salvatore, M. & Lombardi, G. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 81, 2356-2362.
14. Colao, A. Ferone, D., Cappabianca, P., del Basso De Caro, M.L., Marzullo, P., Monticelli, A., Alfieri, A., Merola, B., Cali, A., de Divitiis, E. & Lombardi, G. (1997a) Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 82, 3308-3314.
15. Colao, A., Balzano, A., Ferone, D., Panza, N., Grande, G., Marzullo, P., Bove, A., Iodice, G., Merola, B. & Lombardi, G. (1997b) Increased prevalence of colic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clinical Endocrinology, 47, 23-28.
16. Colao, A., Marzullo, P., Ferone, D., Marinò, V., Pivonello, R., Di Somma, C., Di Sarno, A., Giaccio, A. & Lombardi G. (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. Journal of Endocrinological Investigation 22 40-47.
17. Davies, P.H., Stewart S.E., Lancranjan, L., Sheppard, M.C. & Stewart P.M. (1998) Long term therapy with long-active octreotide (Sandostatin-LAR) for the management of acromegaly. Clinical Endocrinology 48, 311-316.
18. Ezzat, S. & Melmed, S. (1991) Are patients with acromegaly at increased risk for neoplasia? Journal of Clinical Endocrinology and Metabolism, 72, 245-249.
19. Fisker, S., Kaal, A., Montini, M., Pedroncelli, A., Pagani G & Orskov, H. (1997) Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-active octreoticle (Sandostatin-LAR). European Journal of Endocrinology, 136, 61-66.
20. Flogstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1997) Sandostatin LAR in acromegalic patients: long term treatment. Journal of Clinical Endocrinology and Metabolism 82, 23-28.
21. Giusti, M., Gussoni, G., Cuttica, C.M., Giordano, G. & the Italian Multicenter Slow Release Lanreotide Study Group (1996a) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six months report on an Italian multicenter study. Journal of Clinical Endocrinology and Metabolism, 81, 2089-2097.
22. Giusti, M., Arosio, M., Ciccarelli, E., Dallabonzana, D., Delitala, G., Gussoni, G. & Giordano, G. (1996b) Effects of long-term slow release lanreotide treatment in selected patients with active acromegaly. In Pituitary adenomas: from basic research to diagnosis and therapy (Eds., K. Von Werder and, R. Fahlbush), pp. 55-59., B.V. Elsevier Science, Amsterdam.
23. Giusti, M., Ciccarelli, E., Dallabonzana, D., Delitala, G., Faglia, G., Liuzzi, A., Gussoni, G. & Giordano, G. (1997) Clinical results of long-term slow release lanreotide treatment of acromegaly. European Journal of Clinical Investigations, 27, 277-284.
24. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B. & Kuhn, J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 76, 721-72.
25. Hofland, L.J., van Koetsveld, P.M., Waaijers, M., Zuyderwijk, J. & Lamberts, S.W. (1994) Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology, 134, 301-306.
26. Jenkins, P.J., Fairclough, P.D., Richards, T., Lowe, D.G., Monson, J., Grossman, A., Wass, J.A. & Besser, M. (1997) Acromegaly, colonic polyps and carcinoma. Clinical Endocrinology 47, 17-22.
27. Johnson, M.R., Chowdrey, H.S., Thomas, F., Grint, C. & Lightman, S.L. (1994) Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. European Journal of Endocrinology, 130, 229-234.
28. Lamberts, S.W., Uitterlinden, P., Schuijff, P.C. & Klijn, J.G. (1988) Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjiustment and the definition of a biochemical 'cure'. Clinical Endocrinology, 29, 411-420.
29. Marek, J., Hàna, V., Krsek, M., Justovà, V., Catus, F. & Thomas, F. (1994) Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. European Journal of Endocrinology, 131, 20-26.
30. Melmed, S., Jackson, I., Kleinberg, D. & Klibanski, A. (1998) Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism 83, 2646-2652
31. Morange, I., de Boisvilliers, F., Chanson, P., Lucas, B., DeWailly, D., Catus, F., Thomas, F. & Jaquet, P. (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. Journal of Clinical Endocrinology and Metabolism, 79, 145-151.
32. Nabarro, J.D.N. (1987) Acromegaly. Clinical Endocrinology, 26, 481 512.
33. Orme, S.M., McNally, R.J., Cartwright, R.A., Belchetz., P.E. for the United Kingdom Acromegaly Study Group. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
34. Rajasoorya, C., Holdaway, I.M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102
35. Ron, E., Gridley, G., Hrubec, Z., Page, W. Arora, S. & Fraumeni Jr. J.F. (1991) Acromegaly and gastrointestinal cancer. Cancer, 68, 1673-1677.
36. Sassolas, G. (1995) Medical therapy with somatostatin analogues for acromegaly. European Journal of Endocrinology, 133, 675-677.
37. Shimon, I., Yan, X., Taylor, J.E., Weiss, M.H., Culler, M.D. & Melmed, S. (1997) Somatostatin receptors (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumours. Journal of Clinical Investigation, 100, 2386-2392.
38. Stevenaert, A. & Beckers, A. (1996) Presurgical octreotide: treatment in acromegaly. Metabolism, 45, 72-74.
39. Terzolo, M., Tappero, G., Borretta, G., Asnaghi, G., Pia, A., Reimondo, G., Boccuzzi, A., Cesario, F., Rovero, E., Paccotti, P. & Angeli, A. (1994) High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age. Archives of Internal Medicine, 154, 1272-1276.
40. Timsit, J., Chanson, P., Harris, A.G., Grass, P. & Guillausseau, P.J. (1991) Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment. Hormone and Metabolism Research, 23, 48-49.
41. Vance, M.L. & Harris, A.G. (1991) Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine, 151, 1573-1578.
42. Van der Lely, A.J., Harris, A.G. & Lamberts, S.W. (1992) The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clinical Endocrinology, 37, 181-185.
43. Wright, A.D., Hill, D.M., Lowy, C. & Fraser, T.R. (1970) Mortality in acromegaly. Quarterly Journal of Medicine 39, 1-16